TCS, HDFCBANK, SBI Liquid Fund (G)
Ipca Laboratories Ltd.
Ipca Laboratories
NSE
₹ 0.00
0.00 (0.00)%
Healthcare
Mid-cap
With a market cap of ₹18.90L Cr.
Moderate Volatility
Stock is 1.13x as volatile as index
| EX-Date | Purpose |
|---|---|
| 28 05 2021 | Audited Results |
| 05 08 2021 | Quarterly Results |
| 13 11 2021 | Interim Dividend & Stock Split & Quarterly Results |
| 14 02 2022 | Quarterly Results |
| 24 05 2022 | Audited Results & Amalgamation |
| 10 08 2022 | Quarterly Results |
| 11 11 2022 | Quarterly Results & Interim Dividend |
| 14 02 2023 | Quarterly Results |
| 29 05 2023 | Audited Results |
| 10 08 2023 | Quarterly Results |
| 10 11 2023 | Quarterly Results & Interim Dividend |
| 14 02 2024 | Quarterly Results |
| 30 09 2024 | Inter alia, to consider and approve:- (1) Integration and consolidation of the generics formulations business in the US market of M/s. Bayshore Pharmaceuticals LLC (wholly owned step-down subsidiary) into Unichem Pharmaceuticals (USA) Inc. (wholly owned subsidiary of Company?s subsidiary) |
| 14 11 2024 | Quarterly Results & Interim Dividend |
| 13 02 2025 | Quarterly Results |
News
No News data available
